IRISYS
28.7.2020 12:02:09 CEST | Business Wire | Press release
The COVID-19 pandemic has created an urgent need to accurately and efficiently manage occupancy regulations and enable social distancing in corporate workspaces, higher education buildings, retail stores, and manufacturing facilities. The Irisys SafeCount™ Live Occupancy Monitoring Solution helps businesses comply with social distancing and occupancy guidelines by anonymously counting people as they enter and exit buildings and rooms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005318/en/
Suitable for buildings of all sizes, even those with multiple entrances and exits, SafeCount delivers live occupancy data with visual warnings and alerts when limits are approached or exceeded.
Built on the advanced Irisys Vector 4D people counting sensor, SafeCount features:
- Easy, fast installation — Simple setup and configuration in less than 30 minutes.
- Highly accurate — Better than 99 percent sensor accuracy that is unaffected by environmental conditions or large crowds.
- Privacy protection — no personally identifiable information is captured by the system.
- Staff detection — advanced functionality can exclude staff from occupancy count.
- Standalone system, yet scalable — SafeCount works separately from existing IT networks and you can add the optional SafeCount Plus cloud platform for remote management and reporting.
“The Irisys SafeCount dashboard puts real-time occupancy data in the hands of attendants and managers while the historical reports provide an audit trail for social distancing compliance,” said Mike Slevin, director of sales at Irisys “Perhaps more importantly, SafeCount gives customers, employees, and visitors peace of mind that your company is protecting their health and safety.”
The SafeCount Plus cloud platform supports an unlimited number of buildings in different locations and time zones. Its advanced reporting enables managers to easily review, compare and analyze occupancy data to identify locations that are not complying with occupancy restrictions, allowing them to take action.
For more information on Irisys SafeCount Live Occupancy Monitoring, visit: https://www.irisys.net/products/safecount-occupancy-monitoring-solution .
About Irisys
Infrared Integrated Systems Ltd, generally called Irisys, is the largest global provider of people counting and real-time queue management solutions. The company’s technology is use by major organizations globally in sectors varying from retail, banks, transport to leisure facilities and public buildings. The systems give operators an unprecedented insight into their business, giving them the information they need to improve customer service, operational efficiency, and profitability. Companies often find opportunities for rapid improvements in their business, and a quick return on investment.
In 2012, Irisys became part of the Fluke Corporation , a worldwide leader in calibration and handheld test instruments. Fluke is world famous for the durability of its test tools and offers a range of tough electrical test tools, infrared thermometers, thermal imagers, and other devices designed for extreme field use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005318/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
